New Delhi: Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia. The single-dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered. An efficacy level of near 80% is higher than that of many two-dose vaccines.
The announcement in this regard was made by the Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology, and the Russian Direct Investment Fund
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V coronavirus vaccine.
The efficacy rate was calculated based on data obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021.
The infection rate among vaccinated subjects from the 28th day from the date of the injection was only 0.277%. Over the same period, the infection rate among the unvaccinated adult population was 1.349%.
Phase I/II Safety and Immunogenicity Study of the single dose Sputnik Light vaccine was initiated in January 2021, and the interim results were received on March 10, 2021:
The results demonstrated that the vaccine can elicit the development of antigen specific IgG antibodies in 96.9% of volunteers on the 28th day after immunization;
Virus-neutralizing antibodies developed in 91.67% of volunteers on the 28th day post immunization.
Cellular immune response against the S Protein of SARS-CoV-2 developed in 100% of volunteers;
No serious adverse events were registered after vaccination with Sputnik Light;
The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit an increase of the level of IgG antibodies by more than 40x in 100% of volunteers on the 10th day after immunization;
Sputnik Light demonstrated safety for all subjects, including those with pre-existing immunity to SARS-CoV-2.